Versor Investments LP Acquires New Shares in Artivion, Inc. $AORT

Versor Investments LP acquired a new position in Artivion, Inc. (NYSE:AORT) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 15,962 shares of the company’s stock, valued at approximately $676,000.

Other institutional investors also recently bought and sold shares of the company. Smartleaf Asset Management LLC lifted its position in shares of Artivion by 47.7% in the second quarter. Smartleaf Asset Management LLC now owns 1,667 shares of the company’s stock worth $52,000 after buying an additional 538 shares during the last quarter. State of Wyoming bought a new position in shares of Artivion in the 3rd quarter valued at approximately $80,000. Tower Research Capital LLC TRC lifted its holdings in Artivion by 447.6% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,410 shares of the company’s stock worth $168,000 after purchasing an additional 4,422 shares during the last quarter. Diversified Trust Co bought a new stake in Artivion during the third quarter worth approximately $200,000. Finally, James Investment Research Inc. acquired a new position in Artivion during the second quarter valued at approximately $210,000. 86.37% of the stock is currently owned by institutional investors.

Insider Transactions at Artivion

In other Artivion news, SVP Jean F. Holloway sold 7,315 shares of the firm’s stock in a transaction that occurred on Wednesday, December 3rd. The stock was sold at an average price of $45.30, for a total value of $331,369.50. Following the completion of the sale, the senior vice president owned 156,093 shares in the company, valued at approximately $7,071,012.90. This trade represents a 4.48% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO James P. Mackin sold 30,921 shares of Artivion stock in a transaction that occurred on Tuesday, December 2nd. The stock was sold at an average price of $45.56, for a total value of $1,408,760.76. Following the sale, the chief executive officer directly owned 800,993 shares in the company, valued at $36,493,241.08. The trade was a 3.72% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 141,234 shares of company stock worth $6,366,621. 7.60% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on AORT shares. Wall Street Zen cut shares of Artivion from a “strong-buy” rating to a “buy” rating in a research note on Saturday, January 24th. Needham & Company LLC reissued a “buy” rating and set a $58.00 target price on shares of Artivion in a research report on Monday, February 2nd. Oppenheimer reaffirmed an “outperform” rating and issued a $50.00 price target on shares of Artivion in a research report on Friday, November 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Artivion in a research report on Wednesday, January 21st. Finally, Citizens Jmp increased their target price on Artivion from $47.00 to $53.00 and gave the company a “market outperform” rating in a research note on Friday, November 7th. Seven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $49.11.

Artivion Stock Down 0.8%

NYSE AORT opened at $40.04 on Thursday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 2.88 and a current ratio of 3.93. The firm has a 50-day simple moving average of $43.86 and a 200 day simple moving average of $42.77. Artivion, Inc. has a twelve month low of $21.97 and a twelve month high of $48.25. The stock has a market cap of $1.90 billion, a PE ratio of -166.81 and a beta of 1.59.

Artivion Company Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.